You are here

P&T News

May 2

Allergan’s rosuvastatin calcium joins a $6.5 billion market
Subcutaneous nonopioid relieves pain with less toxicity and abuse potential
First and only FDA-approved drug for Parkinson-associated hallucinations and delusions
Registry will provide long-term safety and effectiveness data
Possible link to long wait times for VA care

April 29

First authorized test from commercial lab in U.S.
Combo treatment with lenalidomide and dexamethasone extends progression-free survival
Topoisomerase 1 inhibitors may blunt inflammatory storms

April 28

Medicare EHR incentive system will be phased out
Guidance emphasizes individualized treatment

April 27

Hospitals, insurers, and businesses prod drug-makers
Product overcomes patent-infringement lawsuit

Pages